Patent ID: 8492342

Claim:
A method of immunotherapy for treating a tumour in a subject comprising selecting a subject that expresses HLA-A*0201 and administering to the subject a T epitope peptide presented by MHC I selected from the group consisting of: a) the peptide of sequence: VLLQAGSLHA (SEQ ID NO: 1), b) the peptide of sequence: LVLLQAGSLHA (SEQ ID NO: 2), c) the peptide of SEQ ID NO: 1 having at least one of the following substitutions: the substitution of the N-terminal valine of SEQ ID NO: 1 with a tyrosine, or a leucine; and the substitution of the C-terminal alanine of SEQ ID NO: 1 with a valine or a leucine, and d) the peptide of SEQ ID NO: 2 having at least one of the following substitutions; the substitution of the N-terminal leucine of SEQ ID NO: 2 with a tyrosine; and the substitution of the C-terminal alanine of SEQ ID NO: 2 with a valine or a leucine.